scholarly journals Lessons Learned from Influenza A(H1N1)pdm09 Pandemic Response in Thailand

2012 ◽  
Vol 18 (7) ◽  
Author(s):  
Kumnuan Ungchusak ◽  
Pathom Sawanpanyalert ◽  
Wanna Hanchoworakul ◽  
Narumol Sawanpanyalert ◽  
Susan A. Maloney ◽  
...  
2012 ◽  
Vol 30 ◽  
pp. 49-53 ◽  
Author(s):  
Francisco López-Medrano ◽  
María Carmen Fariñas ◽  
Antonio Payeras ◽  
Jerónimo Pachón

2011 ◽  
Vol 204 (6) ◽  
pp. S1-S3 ◽  
Author(s):  
Denise J. Jamieson ◽  
Sonja A. Rasmussen ◽  
Timothy M. Uyeki ◽  
Cindy Weinbaum

2009 ◽  
Vol 7 (1) ◽  
Author(s):  
José A Córdova-Villalobos ◽  
Elsa Sarti ◽  
Jacqueline Arzoz-Padrés ◽  
Gabriel Manuell-Lee ◽  
Josefina Romero Méndez ◽  
...  

2011 ◽  
Vol 18 (8) ◽  
pp. 1205-1212 ◽  
Author(s):  
Eeva Broberg ◽  
Angus Nicoll ◽  
Andrew Amato-Gauci

ABSTRACTAge-specific seroprevalences for influenza virus make important contributions to estimating the burden of infection and determining the vulnerable populations. It is especially difficult to know the true clinical attack rates of the 2009 influenza A(H1N1) pandemic; however, we can estimate infection rates through analyses of seroprevalences based on national studies from different continents and countries with different demographics. After the 2009 influenza A(H1N1) pandemic, seroprevalence studies found 5 to 60% of populations across different continents and age groups having antibodies against the A(H1N1) 2009 virus. The seropositivity was highest in children and teenagers (20 to 60%) as well as in the elderly older than 80 years (20 to 40%). Preexisting cross-reactive antibodies against the virus were present mostly in sera of older people (born before 1950) who could have encountered viruses descended from the 1918 pandemic viruses. Experience with the 2009 pandemic indicates how essential early and timely serology data against the emerging virus can be for informing decisions on use of antivirals and vaccination campaigns, especially in regard to risk groups. The objectives of this review were to summarize the current data available on seroprevalence before and after the 2009 influenza A(H1N1) pandemic and the lessons learned for future pandemic preparedness.


Sign in / Sign up

Export Citation Format

Share Document